கௌராவ் சந்திரா News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from கௌராவ் சந்திரா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In கௌராவ் சந்திரா Today - Breaking & Trending Today
(1) COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 / In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) (http://enzolytics.com/) and Intel Corporation (https://www.intel.com) has published a thought leadership collaboration. The white paper titled, Optimizing Empathetic A.I. to Cure Deadly Diseases, [https://www.intel.com/content/www/us/en/healthcare-it/resources/enzolytics-whitepaper.html] highlights Intel s Artificial Intelligence Analytic tools and Enzolytic s innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants. This collaborative effort approaches the future of medicine; a future wherein the process of healthcare evolves from reactive to Predictive - Our genetic makeup can predict the diseases we are at risk for. ....
Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good ACCESSWIRE 17 May 2021, 21:05 GMT+10 COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 / In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) (http://enzolytics.com/) and Intel Corporation (https://www.intel.com) has published a thought leadership collaboration. The white paper titled, Optimizing Empathetic A.I. to Cure Deadly Diseases, [https://www.intel.com/content/www/us/en/healthcare-it/resources/enzolytics-whitepaper.html] highlights Intel s Artificial Intelligence Analytic tools and Enzolytic s innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants. ....
Enzolytics, Inc. 2020 Year End Update COLLEGE STATION, TX / ACCESSWIRE / December 30, 2020 / Enzolytics, Inc. (OTC Markets ENZC or the Company ) today shared the following update provided by Enzolytics CEO Charles Cotropia. The full content of the update is presented below. December 30, 2020 To Our Shareholders, On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. ( BCLS or BioClonetics ) entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components - (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested ....
Enzolytics, Inc. 2020 Year End Update December 30, 2020 To Our Shareholders, On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. ( BCLS or BioClonetics ) entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components - (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested in vitro, demonstrating neutralization of over 95% of the HIV isolates against which it was tested and (3) our proprietary methodology for producing fully human monoclonal antibodies which is being used to produce additional anti-HIV monoclonal antibodies targeting additional immutable sites on the HIV virus as w ....
Both management teams were committed to this mission, and even before the completion of the combination documentation, transition of our organizations began by my appointment to the Enzolytics Board as a Director and CEO and appointment of Harry Zhabilov to the BCLS Board. This allowed us to share information for assimilating our proprietary information for research and development purposes and for streamlining the administrative function to accelerate future growth. On December 1, 2020, the combination agreement was completed, and the control block of shares of Enzolytics was transferred in accordance with the terms of the final document to Dr. Joseph Cotropia, Dr. Gaurav Chandra, and me, officially integrating the management teams and organizations into one single-purposed organization. ....